Exploiting Common Genetic Variation to Make Anticoagulation Safer

This publication has 18 references indexed in Scilit:

• Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation
  Stroke, 2008
• The Genetic Architecture of Intracerebral Hemorrhage
  Stroke, 2008
• Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
  Chest, 2008
• Use of Indwelling Pleural Catheters for Chronic Pleural Infection
  Chest, 2008
• Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin
  Clinical Pharmacology & Therapeutics, 2007
• Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages
  The American Journal of Medicine, 2007
• Biomarker qualification pilot process at the US Food and Drug Administration
  The AAPS Journal, 2007
• Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study
  Journal of the American Geriatrics Society, 2006
• The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
  Thrombosis and Haemostasis, 2004
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
  The Lancet, 1999